12.02.2020

AiCuris collaborates with myTomorrows to initiate an Early Access Program for Pritelivir

AiCuris and myTomorrows today announced a collaboration to develop an Early Access Program (EAP) for pritelivir, currently undergoing Phase II testing for treatment of acyclovir-resistant mucocutaneous HSV infections in immunocompromised patients.

more ...